268 related articles for article (PubMed ID: 12020499)
1. Comparison of the effects of an angiotensin-converting enzyme inhibitor and a vasopeptidase inhibitor after myocardial infarction in the rat.
Lapointe N; Blais C; Adam A; Parker T; Sirois MG; Gosselin H; Clément R; Rouleau JL
J Am Coll Cardiol; 2002 May; 39(10):1692-8. PubMed ID: 12020499
[TBL] [Abstract][Full Text] [Related]
2. Effects of captopril and omapatrilat on early post-myocardial infarction survival and cardiac hemodynamics in rats: interaction with cardiac cytokine expression.
Blais C; Lapointe N; Rouleau JL; Clément R; Bachvarov DR; Adam A
Can J Physiol Pharmacol; 2002 Jan; 80(1):48-58. PubMed ID: 11911226
[TBL] [Abstract][Full Text] [Related]
3. Comparative effects of a vasopeptidase inhibitor vs. an angiotensin converting enzyme inhibitor on cardiomyocyte apoptosis in rats with heart failure.
Lapointe N; Tsoporis JN; Parker TG; Blais C; Adam A; Rouleau D; Slaughter G; Clément R; Deschepper CE; Rouleau JL
Mol Cell Biochem; 2003 Dec; 254(1-2):235-45. PubMed ID: 14674703
[TBL] [Abstract][Full Text] [Related]
4. Effect of vasopeptidase inhibitor omapatrilat on cardiomyocyte apoptosis and ventricular remodeling in rat myocardial infarction.
Bäcklund T; Palojoki E; Saraste A; Grönholm T; Eriksson A; Lakkisto P; Vuolteenaho O; Nieminen MS; Voipio-Pulkki LM; Laine M; Tikkanen I
Cardiovasc Res; 2003 Mar; 57(3):727-37. PubMed ID: 12618234
[TBL] [Abstract][Full Text] [Related]
5. Effects of the vasopeptidase inhibitor omapatrilat on cardiac endogenous kinins in rats with acute myocardial infarction.
Blais C; Lapointe N; Rouleau JL; Clément R; Gervais N; Geadah D; Adam A
Peptides; 2001 Jun; 22(6):953-62. PubMed ID: 11390026
[TBL] [Abstract][Full Text] [Related]
6. Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril.
Trippodo NC; Fox M; Monticello TM; Panchal BC; Asaad MM
J Cardiovasc Pharmacol; 1999 Dec; 34(6):782-90. PubMed ID: 10598120
[TBL] [Abstract][Full Text] [Related]
7. Effects of the vasopeptidase inhibitor omapatrilat on peri- and postmyocardial infarction in Zucker lean rats.
Lapointe N; Parker TG; Tsoporis JN; Nguyen QT; Marcotte F; Adam A; Lou I; Rouleau JL
Can J Cardiol; 2005 Mar; 21(3):291-7. PubMed ID: 15776120
[TBL] [Abstract][Full Text] [Related]
8. Effects of pre-, peri-, and postmyocardial infarction treatment with omapatrilat in rats: survival, arrhythmias, ventricular function, and remodeling.
Lapointe N; Nguyen QT; Desjardins JF; Marcotte F; Pourdjabbar A; Moe G; Calderone A; Rouleau JL
Am J Physiol Heart Circ Physiol; 2003 Jul; 285(1):H398-405. PubMed ID: 12663265
[TBL] [Abstract][Full Text] [Related]
9. Direct inhibition of neutral endopeptidase in vasopeptidase inhibitor-mediated amelioration of cardiac remodeling in rats with chronic heart failure.
Maki T; Nasa Y; Tanonaka K; Takahashi M; Takeo S
Mol Cell Biochem; 2003 Dec; 254(1-2):265-73. PubMed ID: 14674706
[TBL] [Abstract][Full Text] [Related]
10. Vasopeptidase inhibition has beneficial cardiac effects in spontaneously diabetic Goto-Kakizaki rats.
Grönholm T; Cheng ZJ; Palojoki E; Eriksson A; Bäcklund T; Vuolteenaho O; Finckenberg P; Laine M; Mervaala E; Tikkanen I
Eur J Pharmacol; 2005 Sep; 519(3):267-76. PubMed ID: 16137672
[TBL] [Abstract][Full Text] [Related]
11. Vasopeptidase inhibition peri- and post-MI in Zucker insulin resistant rats: effect on MI size, arrhythmias, remodeling, function and fetal gene expression.
Lapointe N; Nguyen QT; Desjardins JF; Tsoporis J; Marcotte F; Pourdjabbar A; Parker TG; Moe G; Adam A; Rouleau JL
Cardiovasc Drugs Ther; 2005 Oct; 19(5):323-32. PubMed ID: 16382294
[TBL] [Abstract][Full Text] [Related]
12. Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts.
Blais C; Fortin D; Rouleau JL; Molinaro G; Adam A
J Pharmacol Exp Ther; 2000 Nov; 295(2):621-6. PubMed ID: 11046097
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin I-converting enzyme-dependent and neutral endopeptidase-dependent generation and degradation of angiotensin II contrarily modulate noradrenaline release: implications for vasopeptidase-inhibitor therapy?
Raasch W; Dominiak P; Dendorfer A
J Hypertens; 2005 Aug; 23(8):1597-604. PubMed ID: 16003188
[TBL] [Abstract][Full Text] [Related]
14. Comparison of a vasopeptidase inhibitor with neutral endopeptidase and angiotensin-converting enzyme inhibitors on bradykinin metabolism in the rat coronary bed.
Dumoulin MJ; Adam A; Rouleau JL; Lamontagne D
J Cardiovasc Pharmacol; 2001 Apr; 37(4):359-66. PubMed ID: 11300648
[TBL] [Abstract][Full Text] [Related]
15. Bradykinin metabolism in the postinfarcted rat heart: role of ACE and neutral endopeptidase 24.11.
Raut R; Rouleau JL; Blais C; Gosselin H; Molinaro G; Sirois MG; Lepage Y; Crine P; Adam A
Am J Physiol; 1999 May; 276(5):H1769-79. PubMed ID: 10330262
[TBL] [Abstract][Full Text] [Related]
16. Effects of neutral endopeptidase (neprilysin) inhibition on the response to other vasoactive peptides in small human resistance arteries: studies with thiorphan and omapatrilat.
Dalzell JR; Seed A; Berry C; Whelan CJ; Petrie MC; Padmanabhan N; Clarke A; Biggerstaff F; Hillier C; McMurray JJ
Cardiovasc Ther; 2014 Feb; 32(1):13-8. PubMed ID: 24138103
[TBL] [Abstract][Full Text] [Related]
17. Chronic vasopeptidase inhibition restores endothelin-converting enzyme activity and normalizes endothelin levels in salt-induced hypertension.
Quaschning T; d'Uscio LV; Shaw S; Viswambharan H; Ruschitzka FT; Lüscher TF
Nephrol Dial Transplant; 2001 Jun; 16(6):1176-82. PubMed ID: 11390717
[TBL] [Abstract][Full Text] [Related]
18. Vasopeptidase inhibitor omapatrilat induces profound insulin sensitization and increases myocardial glucose uptake in Zucker fatty rats: Studies comparing a vasopeptidase inhibitor, angiotensin-converting enzyme inhibitor, and angiotensin II type I receptor blocker.
Wang CH; Leung N; Lapointe N; Szeto L; Uffelman KD; Giacca A; Rouleau JL; Lewis GF
Circulation; 2003 Apr; 107(14):1923-9. PubMed ID: 12668518
[TBL] [Abstract][Full Text] [Related]
19. Attenuation of cardiovascular remodeling in DOCA-salt rats by the vasopeptidase inhibitor, omapatrilat.
Loch D; Hoey A; Brown L
Clin Exp Hypertens; 2006 Jul; 28(5):475-88. PubMed ID: 16820344
[TBL] [Abstract][Full Text] [Related]
20. Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study.
Solomon SD; Skali H; Bourgoun M; Fang J; Ghali JK; Martelet M; Wojciechowski D; Ansmite B; Skards J; Laks T; Henry D; Packer M; Pfeffer MA;
Am Heart J; 2005 Aug; 150(2):257-62. PubMed ID: 16086927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
